Evidence map›Paper›PMID 40854111›Full record

ArticleJournal of the National Cancer Institute2026

International neuroblastoma risk group consortium: a model of networking for rare cancers.

Susan L Cohn, Wendy B London, Gudrun Schleiermacher, Lucas Moreno, Inge M Ambros, Peter F Ambros, Rochelle Bagatell, Maja Beck Popovic, Klaus Hermann Beiske, Frank Berthold and 22 more

Abstract read
In one paragraph

Article in Journal of the National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

32 authors.

Susan L CohnDepartment of Pediatrics, Comer Children's Hospital and University of Chicago, Chicago, IL, United States.ORCID 0000-0001-5749-7650
Wendy B LondonDana-Farber/Boston Children's Cancer and Blood Disorders Center, Division of Hematology and Oncology, Department of Pediatrics, Harvard Medical School, Boston, MA, United States.ORCID 0000-0003-3571-6538
Gudrun SchleiermacherSIREDO Integrated Pediatric Oncology Center and U1330 Institut national de la santé et de la recherche médicale (INSERM), Institut Curie Research Center, PSL Research University, Institut Curie, Paris, France.ORCID 0000-0002-0133-5879
Lucas MorenoDepartment of Pediatric Oncology, Vall d'Hebron Hospital, Barcelona, Spain.ORCID 0000-0002-0708-1670
Inge M AmbrosChildren's Cancer Research Institute, Vienna, Austria (retired).ORCID 0009-0002-0621-3210
Peter F AmbrosChildren's Cancer Research Institut, Vienna, Austria (emeritus).ORCID 0000-0002-5507-7211
Rochelle BagatellDepartment of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, United States.ORCID 0000-0002-5729-8819
Maja Beck PopovicFaculty of Biology and Medicine, University Hospital CHUV, Lausanne, Switzerland.ORCID 0000-0001-9502-5697
Klaus Hermann BeiskeInstitute of Clinical Medicine, Medical Faculty, University of Oslo, Oslo, Norway.ORCID 0000-0002-7772-7748
Frank BertholdDepartment of Pediatric Oncology and Hematology, University of Cologne, Cologne, Germany (retired).ORCID 0000-0002-7613-1723
Suzi BirzDepartment of Pediatrics, Data for the Common Good, University of Chicago, Chicago, IL, United States.ORCID 0000-0002-9512-799X
Hervé J BrisseImaging Department, Institut Curie and Université Paris Sciences et Lettres, Paris, France.ORCID 0000-0003-2794-5875
Garrett M BrodeurDepartment of Pediatrics, Children's Hospital of Philadelphia, Philadelphia, PA, United States.ORCID 0000-0002-6721-122X
Penelope R BrockDepartment of Paediatric Oncology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, United Kingdom (retired).ORCID 0000-0003-1239-6316
Susan BurchillChildren's Cancer Research Group, Leeds Institute of Medical Research, St James's University Hospital, Leeds, United Kingdom.
Angelika EggertDepartment of Pediatric Oncology/Hematology, Charité - Universitätsmedizin, Berlin, Germany.
Sara M FedericoDepartment of Oncology, St Jude Children's Research Hospital, Memphis, TN, United States.
Matthias FischerDepartment of Experimental Pediatric Oncology, University Children's Hospital, Medical Faculty, Center for Molecular Medicine Cologne, University of Cologne, Germany.ORCID 0000-0003-1363-1242
Brian T FurnerDepartment of Pediatrics, Data for the Common Good, University of Chicago, Chicago, IL, United States.ORCID 0000-0001-7074-7247
Barbara HeroDepartment of Pediatric Oncology and Hematology, University Children's Hospital, Medical Faculty University of Cologne, Köln, Germany.ORCID 0000-0003-4129-890X
David MachinUniversity of Leicester, United Kingdom (retired).
Takehiko KamijoResearch Institute for Clinical Oncology, Saitama Cancer Center, Saitama, Japan.ORCID 0000-0003-4798-7546
Katherine K MatthayDepartment of Pediatrics, University of California San Francisco (UCSF) School of Medicine and UCSF Benioff Children's Hospital, San Francisco, CA, United States.ORCID 0000-0002-0146-2499
Akira NakagawaraSaga International Carbon Particle Beam Radiation Cancer Therapy Center, Saga HIMAT Foundation, Saga, Japan.ORCID 0000-0003-3732-7763
Arlene NaranjoDepartment of Biostatistics, University of Florida Children's Oncology Group Statistics and Data Center, Gainesville, FL, United States.ORCID 0000-0001-7737-4324
Ulrike PötschgerSt Anna Children's Cancer Research Institute, Vienna, Austria.ORCID 0000-0001-7024-7082
Dominique Valteau-CouanetDepartment of Pediatric and Adolescent Oncology, Gustave Roussy Cancer Campus Grand-Paris, Villejuif Cedex, France (retired).
Michael T WatkinsDepartment of Pediatrics, Data for the Common Good, University of Chicago, Chicago, IL, United States.ORCID 0000-0003-0613-1127
Meredith S IrwinDepartment of Pediatrics, Hospital for Sick Children, University of Toronto, Toronto, Canada.ORCID 0000-0002-2452-5181
Samuel L VolchenboumDepartment of Pediatrics, Data for the Common Good, University of Chicago, Chicago, IL, United States.ORCID 0000-0001-9863-851X
Julie R ParkDepartment of Oncology, St Jude Children's Research Hospital, Memphis, TN, United States.ORCID 0000-0002-6777-9165
Andrew D J PearsonThe Royal Marsden Hospital and The Institute of Cancer Research, London, United Kingdom (retired).ORCID 0000-0002-8738-5913

Funding

Alex's Lemonade Stand FoundationChildren's Cancer Research FundLittle Heroes Pediatric Cancer FoundationMatthew Bittker FoundationNeuroblastoma Children's Cancer SocietyRally Foundation for Childhood Cancer ResearchSammy's SuperheroesSt Baldrick's FoundationWilliam Guy Forbeck Research Foundation
6 · The paper itself

Abstract

It is critical to share knowledge and harmonize approaches to optimize progress in rare cancers. The International Neuroblastoma Risk Group (INRG) Task Force was formed by the 4 major neuroblastoma cooperative groups in 2004 to achieve this goal. Strategies developed for neuroblastoma are an exemplar for other rare malignancies. Data from an initial cohort of 8800 patients were transferred to the INRG Data Commons, and a data-sharing model was developed. Currently, information on more than 25 000 patients is available to the research community. The INRG staging and risk classification systems have led to harmonized approaches for therapeutic groupings. INRG consensus manuscripts have led to uniform criteria for classifying biological data, evaluating the extent of disease, and defining treatment response. More than 40 INRG research studies have been performed by investigators from around the world, including analyses of rare patients, which would not otherwise be possible. The success of this approach for neuroblastoma has been leveraged to create the Pediatric Cancer Data Commons and the Data for the Common Good. Efforts to enrich the INRG Commons with additional genomic and biomarker data, extracted electronic health records, and digital medical images are ongoing. The international networking model developed by the INRG Task Force has led to new research discoveries and progress in neuroblastoma. The approach has now been applied to 16 other cancers and conditions, including rhabdomyosarcoma, germ cell tumor, Lynch syndrome, and cancer predisposition. This framework of international collaboration and data sharing serves as a model for advancing rare adult malignancies.

Indexed as

NeuroblastomaRare DiseasesHumansInformation Dissemination

Identifiers

PMID40854111
PMCPMC13064493

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.